Due Diligence (7)

Challenge A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment.

Challenge Our client asked us to conduct a risk assessment and due diligence of a small molecule oncology compound that had been identified from a phenotypic screen. The molecule was in a Phase I/II...

Challenge We were commissioned to conduct a comprehensive technical risk assessment and due diligence of a novel preclinical, small molecule, kinase inhibitor.

Challenge A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...

Challenge A clinical stage, type 1 diabetes immunotherapy project needed convincing partnering materials and advice on data room structure and due diligence preparations.

Challenge A European pharma company needed to conduct an expert reality check on a pain in-licensing opportunity.

Challenge An established medical device company looking to make a strategic investment needed commercial, regulatory, IP and technical due diligence on an investment opportunity in the diabetes...

Challenge A major UK bioscience investor needed due diligence on a cell biology reagents investment opportunity.

Challenge An incoming lead investor needed to assess a proprietary platform technology for the oral delivery of biological drugs.

Challenge A pharma company looking to purchase an asset needed a respiratory consultant to conduct clinical due diligence of a Phase II biologic designed to treat a respiratory condition.

Challenge A well-capitalized strategic investor looking to enter the radiopharmaceuticals market wanted to conduct clinical due diligence on a novel radioisotope-conjugated antibody designed to treat...

Challenge Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the US. One target company was developing a new...